J&J Reports 77% Response Rate in HPV-Unrelated Head and Neck Cancer Group

The rate was 66% across all 29 evaluable participants. A randomized Phase 3 study will compare the regimen with pembrolizumab, platinum chemotherapy and 5-fluorouracil.

Leave a Reply

Your email address will not be published. Required fields are marked *

UP NEXT

Related Tags

Loading RSS Feed

You May Like

Subscribe To Our Newsletter

Metus in ac vivamus dui id purus in risus. Nunc fringilla donec amet pulvinar vivamus suscipit. Augue porttitor eu sed proin tortor bibendum facilisis felis. Nunc egestas tellus nisl tempor aliquet malesuada ali eu sed proin tortor bibendum facilisis felis
Stay Updated by our Monthly / Weekly News Update. Zero Spamming. Terms & Condition Applied